Example of an investigation of an "emergent" phenomenon in addiction vigilance: The case of methylphenidate;Un exemple d'investigation d'un phénomène « émergent » en addictovigilance: à propos du méthylphénidate

Therapie

Volumn 70, Issue 2, 2015, Pages 191-196

  Micallef, Joëlle ^a   Frauger, Elisabeth ^a   Palmaro, Aurore ^b   Boucherie, Quentin ^a   Lapeyre Mestre, Maryse ^b  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; ARTICLE; FRANCE; PRIORITY JOURNAL; BEHAVIOR DISORDER; DISEASE SURVEILLANCE; DRUG ABUSE; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; DRUG USE; HEALTH PRACTITIONER; HUMAN; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PUBLIC HEALTH; PUBLIC HEALTH PROBLEM; FACTUAL DATABASE; HEALTH SURVEY; PRESCRIPTION DRUG MISUSE; SUBSTANCE-RELATED DISORDERS;

METHYLPHENIDATE; CENTRAL STIMULANT AGENT; PSYCHOTROPIC AGENT;

CENTRAL NERVOUS SYSTEM STIMULANTS; DATABASES, FACTUAL; FRANCE; HUMANS; METHYLPHENIDATE; PHARMACOVIGILANCE; POPULATION SURVEILLANCE; PRESCRIPTION DRUG MISUSE; PSYCHOTROPIC DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84928043015     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2015012     Document Type: Article

References (38)

1. Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side Effects. Prim Care Companion J Clin Psychiatry 2000; 2 (5): 159-64
2. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003, 160 (11): 1909-18
3. Frances C, Hoizey G, Millart H, et al. Paediatric methylphenidate (Ritalin) restrictive conditions of prescription in France. Br J Clin Pharmacol 2004; 57: 115-6
4. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction 2012; 107(3): 467-77
5. Frauger E, Pauly V, Natali F, et al. Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. CNS Drugs 2011 May 1; 25(5): 415-24
6. Frauger E, Moracchini C, Le Boisselier R, et al. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol 2013 Dec; 27(6): 672-82
7. Frauger E, Spadari M, Djezzar S, et al. Étude des pratiques d'injection intraveineuse et autres détournements du méthylphénidate (région PACACorse). Le Courrier des addictions 2011; 13: 15-20
8. Ehrhardt C, Boucherie Q, Pauly V, et al. Trends in methylphenidate dispensing from 2005 to 2011. Fundam Clin Pharmacol 2014; 28 (Suppl 1): 21 (A093)
9. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Méthylphénidate: données d'utilisation et de sécurité d'emploi en France. Juillet 2013 http://ansm.sante.fr/var/ansm-site/storage/original/application/8dd1277a3867155547b4dce58fc0db00.pdf Consulté le 24 décembre 2014 (26 pages)
10. Treceño C, Martín Arias LH, Sáinz M, et al. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf 2012 Apr; 21(4): 435-41
11. Trip AM, Visser ST, Kalverdijk LJ, et al. Large increase of the use of psychostimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 2009 Apr; 67(4): 466-8
12. Zoëga H, Furu K, Halldórsson M, et al. Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr Scand 2011 May; 123(5): 360-7
13. Pottegard A, Bjerregaard BK, Glintborg D, et al. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol 2013 Mar; 69(3): 589-98
14. Lapeyre-Mestre M, Gony M, Carvajal A, et al. A European community pharmacy- based survey to investigate patterns of prescription fraud through identification of falsified prescriptions. Eur Addict Res 2014; 20(4): 174-82
15. Bruggisser M, Ceschi A, Bodmer M, et al. Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997-2009. Swiss Med Wkly 2010; 140: w13115
16. Bruggisser M, Bodmer M, Liechti M. Severe toxicity due to injected but no t oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly 2011 Oct 9; 141: w13267
17. Livio F, Rauber-Lüthy C, Biollaz J, et al. Methylphénidate et abus. Paediatrica 2009; Vol. 20 No. 5: 41-4 http://www.swiss-paediatrics.org/sites/default/files/paediatrica/vol20/n5/pdf/41-44.pdf Consulté le 24 décembre 2014 (4 page)
18. Bjarnadottir GD, Rafnar BO, Sigurdsson E, et al. Methylphenidate use among Icelandic i.v. substance abusers. European Psychiatry 2013, 28 (suppl 1): P703
19. Geirs DP, Pottegard A, Halldórsson M, et al. A nationwide study of ADHD drug use among adults in Iceland 2003-2012. Basic Clin Pharmacol Toxicol 2014 Apr 1 DOI: 10.1111/bcpt.12243
20. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006; 54: 269-78
21. Wright ER, Kooreman HE, Greene MS, et al. The iatrogenic epidemic of prescription drug abuse: county-level determinants of opioid availability and abuse. Drug Alcohol Depend 2014 May 1; 138: 209-15
22. Le Lait MC, Martinez EM, Severtson SG, et al. Assessment of prescription opioid intentional exposures across the rural-urban continuum in the United States using both population and drug availability rates. Pharmacoepidemiol Drug Saf 2014 Dec; 23(12): 1334-7
23. Swanson JM, Volkow ND. Increasing use of stimulants warns of potential abuse. Nature 2008; 453(7195): 586
24. Micallef J, Star K, Palmaro A, et al. Detection and magnitude of methylphenidate abuse and misuse using vigibase and correlation with level of use in Europe [poster, abstract]. Pharmacoepidemiol Drug Saf 2012; 21: 450
25. Lapeyre-Mestre M, Sapède C, Moore N, et al. Pharmacoepidemiology studies: what levels of evidence and how can they be reached? Therapie 2013; 68(4): 241-52
26. Micaleff J, Jolliet P, Victorri-Vigneau C, et al. First meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Assessment of the abuse and pharmacodependence potential during drug development. Therapie 2008; 63(1): 55-65
27. Daveluy A, Thirion X. Vigilance sanitaire et agences régionales de santé: quelle évaluation régionale du risque d'abus et d'abus et d'addiction aux stupéfiants et aux psychotropes? La Lettre du Pharmacologue 2011; 25(2): 57-61
28. Moracchini C, Frauger E, Pauly V, et al. Harm reduction centers ("CAARUD"): privileged places for warning signal detection in addictovigilance. Therapie 2012; 67(5): 437-45
29. Nordmann S, Pradel V, Lapeyre-Mestre M, et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician 2013 Jan; 16(1): 89-100
30. Brownstein JS, Green TC, Cassidy TA, et al. Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiol Drug Saf 2010 Jun; 19(6): 627-37
31. Micallef J, Pradel V, Thirion X, et al. Use of the health insurance database by the centres for evaluation and information on pharmacodependance: examples, interests and future prospects. Therapie 2004 Nov-Dec; 59(6): 581-8
32. Begaud B, Costagliola D. Rapport sur la surveillance et la promotion du bon usage du médicament. Rapport Ministère des Affaires Sociales et de la Santé, 2013 http://www.sante.gouv.fr/IMG/pdf/Rapport-Begaud-Costagliola.pdf Consulté le 24 décembre 2014 (54 pages)
33. Gahr M, Freudenmann RW, Hiemke C, et al. Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions. Psychiatry Res 2014 Jan 30; 215(1): 252-4
34. Organisation Mondiale de la Santé. Comité OMS d'experts de la pharmacodépendance. Série de rapports techniques 973. Trente-cinquième rapport, 2012 http://apps.who.int/iris/bitstream/10665/78615/1/WHO-TRS-973-fre.pdf Consulté le 24 décembre 2014 (39 pages)
35. Karlstad O, Furu K, Skurtveit S, et al. Prescribing of drugs for attentiondeficit hyperactivity disorder in opioid maintenance treatment patients in Norway. Eur Addict Res 2013, 20(2): 59-65
36. Pérez de Los Cobos J, Siñol N, Pérez V, et al. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol 2014; 77(2): 337-56
37. INSERM. Expertises collectives. Medicaments psychotropes. Consommations et pharmacodépendances. 2012 http://www.inserm.fr/content/download/62753/417059/file/Medicamentspsychotropes-fascicule-corpus.pdf Consulté le 24 décembre 2014 (118 pages)
38. Lapeyre Mestre M. Addiction médicamenteuse: quelles données pour évaluer et prévenir? Psychotropes 2013; 19: 65-80